Translational proteomics: what can you do for true patients?

Area of Science:

• Oncology
• Proteomics
• Translational Medicine

Background:

• Modern oncology increasingly relies on personalized medicine, targeting specific cancer cell proteins.
• Current clinical decisions heavily depend on histology and TNM staging, alongside traditional chemotherapy agents.
• A dual approach integrating novel targeted therapies with surgery, radiotherapy, and chemotherapy is emerging.

Purpose of the Study:

• To identify unmet needs for clinical oncologists in the era of personalized cancer care.
• To explore how cancer proteomics can provide greater value for individual patient treatment strategies.
• To bridge the gap between advanced molecular targeting and current clinical practice.

Main Methods:

• Review of current oncological treatment paradigms.
• Analysis of the role of biomarkers in therapeutic decision-making.
• Exploration of the potential of proteomics in clinical oncology.

Main Results:

• Histology and TNM staging remain primary biomarkers despite advances in targeted therapies.
• Classical chemotherapeutic drugs are still widely used alongside emerging treatments.
• A significant need exists to better integrate proteomic data into clinical oncology workflows.

Conclusions:

• Clinical oncology faces a duality of traditional and novel therapeutic approaches.
• Unmet needs in clinical oncology can be addressed by leveraging cancer proteomics.
• Enhanced integration of proteomic insights is crucial for advancing patient-centered cancer care.